Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | RAB9A | P51151 | 10/20 | 0.62 |
| ▸ | NPC1 | O15118 | 8/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835357 | 0.89 | RXFP1 (0.70) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL4393473 | 0.86 | RXFP1 (0.53) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL4516696 | 0.85 | RXFP1 (0.66) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL1592594 | 0.82 | RXFP1 (0.62) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL1911610 | 0.82 | RXFP1 (0.62) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL3604834 | 0.82 | RXFP1 (0.62) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL28508629 | 0.82 | ALDH1A1 (0.77) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL2559879 | 0.82 | ALDH1A1 (0.76) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL364881 | 0.81 | RXFP1 (0.49) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL7923956 | 0.81 | ALDH1A1 (0.70) | RXFP1GAACYP1A2CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550486-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| CN-101296911-A | Arylurea derivatives as modulators of chemokine receptor activity | NOVARTIS AG (CH) | 2008-10-29 | — | — | CN | disclosed |
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-05 | — | — | US | disclosed |
| US-7351720-B2 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-1631286-A4 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1631286-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004110993-A2 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040259914-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132523-A1 | N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ACKR3, CCR7, CCR2 | RXFP1 184/4885GAA 3643/4885CYP1A2 3241/4885 |
| US-20040259914-A1 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | ACKR3, CCR1, CXCR1 | RXFP1 124/4885GAA 3829/4885CYP1A2 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.